Dechra Veterinary Products is committed to developing new products and services that support the equine industry and continue to invest in products and added-value services that deliver our promise to veterinary professionals and owners. Dechra currently markets key equine products including OSPHOS® (clodronate injection) which is an intramuscular bisphosphonate injection indicated for the clinical signs associated with navicular syndrome in horses. Our regenerative medicine portfolio includes the Orthokine® vet irap 10mL and 60mL devices which produce ACS (Autologous Conditioned Serum), a cytokine-rich serum using the horse’s own blood which is then injected into the joint. This is the original and proven irap system first introduced into the market in 2005 and is still the only closed system on the market. We also market Osteokine® which is a Platelet Rich Plasma processing device with a double spin system to give you the highest platelet yield as well as Equidone® Gel (domperidone) for the prevention of fescue toxicosis in periparturient mares. Dechra recently started marketing the only Equine joint supplement on the market with the patented ingredient phycocyanin called PHYCOX®EQ and PHYCOX® EQ MAX which contains 3X the amount of phycocyanin plus a proprietary blend of antioxidants to for overall joint, bone and muscle health.
7015 College Blvd.,
Overland Park, Kansas 66211